Craig A. Stump
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Migraine and Headache Studies, Neuropeptides and Animal Physiology, Neuroscience and Neuropharmacology Research, Protein Kinase Regulation and GTPase Signaling, Sleep and Wakefulness Research
Most-Cited Works
- → Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target(2013)93 cited
- → Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist(2010)63 cited
- → Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead(2006)52 cited
- → Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine(2006)51 cited
- → Structural characterization of nonactive site, TrkA-selective kinase inhibitors(2016)48 cited
- → N-Arylpiperazinone Inhibitors of Farnesyltransferase: Discovery and Biological Activity(1999)45 cited
- → Caprolactams as potent CGRP receptor antagonists for the treatment of migraine(2007)37 cited
- → Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists(2006)37 cited
- → The discovery of highly potent CGRP receptor antagonists(2008)35 cited
- → MK-8825: A potent and selective CGRP receptor antagonist with good oral activity in rats(2012)28 cited